Active, not recruitingPhase 3NCT00470223

Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma

Studying Bone sarcoma

Last synced from ClinicalTrials.gov May 5, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: UNICANCER
Principal Investigator: Laurence Brugieres, MD
Gustave Roussy, Cancer Campus, Grand Paris
Intervention: cisplatin(drug)
Enrollment: 318 enrolled
Eligibility: 5-50 years · All sexes
Timeline: 2007 – 2026

Study locations (30)

Centre Paul Papin, Angers, France
Institut Gustave Roussy, Angers, France
Centre Hospitalier Regional de Besancon - Hopital Jean Minjoz, Besançon, France
CHR de Besancon - Hopital Saint-Jacques, Besançon, France
Institut Bergonie, Bordeaux, France
CHU Hopital A. Morvan, Brest, France
CHU de Caen, Caen, France
Centre Regional Francois Baclesse, Caen, France
CHR Clermont Ferrand, Hotel Dieu, Clermont-Ferrand, France
Centre Jean Perrin, Clermont-Ferrand, France
Centre de Lutte Contre le Cancer Georges-Francois Leclerc, Dijon, France
Centre Hospitalier Universitaire de Dijon, Dijon, France
CHU de Grenoble - Hopital Michallon, Grenoble, France
Centre Oscar Lambret, Lille, France
Centre Leon Berard, Lyon, France
+15 more locations on ClinicalTrials.gov

Collaborators

Novartis · Chugai Pharmaceutical · National Cancer Institute, France · SFCE · Ligue contre le cancer, France

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00470223 on ClinicalTrials.gov

Other trials for Bone sarcoma

Additional recruiting or active studies for the same condition.

See all trials for Bone sarcoma →

← Back to all trials